• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

    2/14/22 6:18:22 AM ET
    $ELOX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ELOX alert in real time by email
    SC 13G/A 1 tm226482d2_sc13ga.htm SC 13G/A

    CUSIP No. 29014R103

    SCHEDULE 13G/A Page 1 of 6

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    _________________

     

    SCHEDULE 13G/A

    _________________

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Eloxx Pharmaceuticals, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    29014R103
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ¨Rule 13d-1(c)

     

    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 29014R103

    SCHEDULE 13G/APage 2 of 6

     

     

    1. NAMES OF REPORTING PERSONS
    Roche Finance Ltd
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a) ¨
      (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland 

    NUMBER OF 5. SOLE VOTING POWER 0
    SHARES    
    BENEFICIALLY    
    OWNED BY 6.

    SHARED VOTING POWER 4,998,936

     

    EACH    
    REPORTING 7.

    SOLE DISPOSITIVE POWER 0

     

    PERSON WITH    
      8.

    SHARED DISPOSITIVE POWER 4,998,936

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,998,936

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.8%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

           

     

    CUSIP No. 29014R103

    SCHEDULE 13G/APage 3 of 6

     

     

    1. NAMES OF REPORTING PERSONS
    Roche Holding Ltd
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
      (a) ¨
      (b) ¨
    3.

    SEC USE ONLY

     

    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Switzerland 

    NUMBER OF 5. SOLE VOTING POWER 0
    SHARES    
    BENEFICIALLY    
    OWNED BY 6.

    SHARED VOTING POWER 4,998,936

     

    EACH    
    REPORTING 7.

    SOLE DISPOSITIVE POWER 0

     

    PERSON WITH    
      8.

    SHARED DISPOSITIVE POWER 4,998,936

     

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,998,936

    10.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See Instructions)

    ¨

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

    5.8%

    12.

    TYPE OF REPORTING PERSON (See Instructions)

     

    CO

           

     

     

    CUSIP No. 29014R103

    SCHEDULE 13G/APage 4 of 6

     

     

    Item 1(a).Name of Issuer:

     

    Eloxx Pharmaceuticals, Inc., a Delaware corporation (the “Issuer”).

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    480 Arsenal Way, Watertown, Massachusetts 02472

     

    Item 2.

     

    (a) Name of Person Filing: Roche Finance Ltd and Roche Holding Ltd

     

    (b) Address or principal business office or, if none, residence:

     

    Roche Finance Ltd: Grenzacherstrasse 122, 4070 Basel, Switzerland.

     

    Roche Holding Ltd: Grenzacherstrasse 124, 4070 Basel, Switzerland.

     

    (c) Citizenship:

     

    Roche Finance Ltd: Switzerland

     

    Roche Holding Ltd: Switzerland

     

    (d) Title of Class of Securities: Common Stock, par value, $0.01 per share.

     

    (e) CUSIP No.: 29014R103.

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Item 4.Ownership:

     

    (a)Each of the Reporting Persons may be deemed to beneficially own 4,998,936 shares of Common Stock.*

     

    (b)Percent of Class: Each Reporting Person may be deemed to beneficially own 5.8%, based on 86,252,365 shares of Common Stock outstanding as of November 3, 2021 as reported in the Issuer’s Quarterly Report on Form 10-Q for the period ended September 30, 2021.*

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote: 0.

     

    (ii)Shared power to vote or to direct the vote: 4,998,936.

     

    (iii)Sole power to dispose or to direct the disposition of: 0.

     

    (iv)Shared power to dispose or to direct the disposition of: 4,998,936.

     

    *Roche Holding Ltd may be deemed to have beneficial ownership of the 4,998,936 shares directly beneficially owned by Roche Finance Ltd, its wholly-owned subsidiary.

     

     

    CUSIP No. 29014R103

    SCHEDULE 13G/APage 5 of 6

     

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ¨.

     

    Not applicable.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person:

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

     

    Roche Finance Ltd is a wholly-owned subsidiary of Roche Holding Ltd.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group:

     

    Not applicable.

     

    Item 10.Certification:

     

    Not applicable.

     

     

    CUSIP No. 29014R103

    SCHEDULE 13G/APage 6 of 6

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of their knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated this 14th day of February, 2022.

     

      ROCHE FINANCE LTD
       
          
      By:  /s/ Carole Nuechterlein
      Carole Nuechterlein, Authorized Signatory
          
          
      By:  /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
          
          
      ROCHE HOLDING LTD
       
          
      By:  /s/ Beat Kraehenmann
      Beat Kraehenmann, Authorized Signatory
          
          
      By:  /s/ Claudia Boeckstiegel
      Claudia Boeckstiegel, Authorized Signatory

     

     

    Get the next $ELOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ELOX

    DatePrice TargetRatingAnalyst
    12/17/2021$4.00Outperform
    Oppenheimer
    11/18/2021$2.00 → $1.00Neutral
    HC Wainwright & Co.
    11/11/2021$3.00 → $2.00Neutral
    HC Wainwright & Co.
    6/30/2021$3.10Buy
    Mizuho
    More analyst ratings

    $ELOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Eloxx Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Eloxx Pharmaceuticals with a rating of Outperform and set a new price target of $4.00

      12/17/21 5:45:41 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $1.00 from $2.00 previously

      11/18/21 6:16:16 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Eloxx Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Eloxx Pharmaceuticals with a rating of Neutral and set a new price target of $2.00 from $3.00 previously

      11/11/21 6:39:05 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Financials

    Live finance-specific insights

    See more
    • Eloxx Pharmaceuticals Reports Topline Results from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients

      Combination of subcutaneous ELX-02 with ivacaftor did not achieve statistical significance for efficacy endpoints in Phase 2 study in Class 1 CF ELX-02 was well tolerated with no drug-related serious adverse events observed Evidence of activity for ELX-02 observed; efficacy signal potentially confounded by variability due to low drug exposure Path forward for ELX-02 for the treatment of Class 1 CF to be determined together with CF Foundation Company to host conference call and webcast today, September 14, 2022, at 4:30 p.m. ET WATERTOWN, Mass., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare d

      9/14/22 4:05:00 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Reports Positive Topline Results from Monotherapy Arms of Phase 2 Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients

      ELX-02 monotherapy dosed at 1.5mg/kg/day demonstrated a statistically significant 5.4mmol/L mean sweat chloride reduction, an established surrogate for restoration of CFTR biological activity ELX-02 monotherapy results support advancement of ELX-02 into Phase 3 clinical development First patient dosed in Phase 2 ELX-02 expansion treatment arms evaluating combination with ivacaftor; topline data expected by the end of the first half of 2022 Company to host conference call and webcast Wednesday, November 17, 2021 at 8:30 am ET WATERTOWN, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ:ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare dise

      11/17/21 7:00:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eloxx Pharmaceuticals Acquires Zikani Therapeutics

      Combined Company to be Leader in Ribosomal RNA-Targeted Genetic Therapy Bringing Together Complementary Platforms Maximizes Potential for ELX-02 for Cystic Fibrosis in Phase 2 Development Adds Preclinical Stage Pipeline in Rare Diseases and Oncology Targeting RNA and Ribosomal Mutations Expects to File IND for First Oral Drug to Treat Patients with Recessive Dystrophic and Junctional Epidermolysis Bullosa (RDEB and JEB) Sumit Aggarwal, Zikani President and CEO, to Lead the Combined Company Eloxx to Issue Approximately 7.6 Million Shares to Zikani Stockholders Company to Host Investor Call at 8:30 a.m. ET, April 1 WALTHAM, Mass. and WATERTOWN, Mass., April 01, 2021 (GLOBE NEWSWIRE

      4/1/21 7:45:00 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ELOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Eloxx Pharmaceuticals Inc.

      SC 13D/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      8/20/24 8:13:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/13/23 4:52:16 PM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Eloxx Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Eloxx Pharmaceuticals, Inc. (0001035354) (Subject)

      2/14/22 6:18:22 AM ET
      $ELOX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care